Ciara Curtin's profile photo

Ciara Curtin

Atlanta

Senior Editor at GenomeWeb

I am a science writer and editor. I also like food, running, and yoga. All views expressed here are my own.

Featured in: Favicon genomeweb.com Favicon scientificamerican.com Favicon modernhealthcare.com Favicon spectrumnews.org Favicon 360dx.com Favicon precisiononcologynews.com Favicon precisionmedicineonline.com

Articles

  • Tenaya's Hypertrophic Cardiomyopathy Gene Therapy Well Tolerated in Interim MyPEAK-1 Trial Data

    3 weeks ago | precisionmedicineonline.com | Ciara Curtin

    CHICAGO – Treatment with Tenaya Therapeutics' investigational gene therapy, TN-201, for MYBPC3-associated hypertrophic cardiomyopathy (HCM) was well tolerated and led to symptom improvement, according to interim clinical trial data. Milind Desai, director of the Hypertrophic Cardiomyopathy Center at Cleveland Clinic and an investigator on the trial, presented the first-in-human data from the Phase Ib/II MyPEAK-1 trial at the American College of Cardiology's annual meeting on Monday.

  • AI Analysis of Routine Cardiac Tests May Serve as Screen to Identify Undiagnosed ATTR-CM

    3 weeks ago | precisionmedicineonline.com | Ciara Curtin

    CHICAGO – Artificial intelligence-fueled analysis of routine cardiac testing may uncover otherwise overlooked cases of transthyretin cardiac amyloidosis (ATTR-CM), according to a new analysis presented Saturday at the American College of Cardiology's annual meeting. ATTR-CM is a severe and progressive disease marked by the accumulation of abnormal transthyretin (TTR) proteins in the heart and leads to heart failure.

  • Plasma Proteomic Profiling Predicts Prognosis, Response to Treatment in Some ATTR-CM Patients

    3 weeks ago | precisionmedicineonline.com | Ciara Curtin

    CHICAGO – Signals from the plasma proteome may help identify which transthyretin cardiac amyloidosis (ATTR-CM) patients will respond better to therapy, early-stage research presented Saturday at the American College of Cardiology's annual meeting suggests.

  • Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce

    2 months ago | precisionmedicineonline.com | Jessica Cohen |Alison Kanski |Catherine Shaffer |Ciara Curtin

    NEW YORK – The life sciences sector is still reeling from the announcement last week that the US National Institutes of Health intends to limit indirect costs for research grants to15 percent. The policy has those in the precision medicine space particularly worried about the effect this may have on the bourgeoning field's ability to continue to develop advanced treatments like cell and gene therapies and maintain an expert workforce.

  • Merck Talks Up Pipeline Diversification as Demand for Keytruda, Facing Patent Expirations, Grows

    2 months ago | precisionmedicineonline.com | Ciara Curtin

    NEW YORK – Merck in a call with investors to discuss its fourth quarter and full-year 2024 financial results highlighted efforts to diversify its pipeline as it faces patent expirations later this decade of its blockbuster immune checkpoint inhibitor Keytruda (pembrolizumab).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
136
Tweets
557
DMs Open
No
Ciara Curtin
Ciara Curtin @ciarzc
4 Nov 24

RT @ATLUTD: THAT'S HOW WE DO IT IN ATLANTA. #UniteThe404 https://t.co/6JrzS5Z4UZ

Ciara Curtin
Ciara Curtin @ciarzc
31 Oct 23

RT @JessicaKimCohen: A spate of consortiums, non-profits & research efforts are cropping up to build momentum for antisense oligonucleotide…

Ciara Curtin
Ciara Curtin @ciarzc
22 Oct 23

RT @Ch_Hops: Lots of #precisiononcology #cancertreatment news coming out of Madrid this weekend. Here's a little thread of my indefatigable…